Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nipocalimab in Healthy Chinese Adults
NCT05151692Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nipocalimab in myasthenia gravis (MG), hemolytic disease of the fetus and newborn (HDFN) and warm autoimmune hemolytic anemia (wAIHA) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Area Under the Serum Concentration Versus Time Curve From Time Zero to Time of the Last Measurable Concentration, Area Under the Analyte Concentration Versus Time Curve From Time Zero to Infinite Time and 7 more. Started May 2022; status: completed.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)hemolytic disease of the fetus and newborn (HDFN)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT05151692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151692.